This articlemay be too technical for most readers to understand. Pleasehelp improve it tomake it understandable to non-experts, without removing the technical details.(May 2023) (Learn how and when to remove this message) |
| Names | |||
|---|---|---|---|
| IUPAC name 1-Methyl-3-(2-methylpropyl)-7H-purine-2,6-dione | |||
| Other names 3-Isobutyl-1-methylxanthine | |||
| Identifiers | |||
3D model (JSmol) | |||
| ChEBI | |||
| ChEMBL | |||
| ChemSpider |
| ||
| DrugBank |
| ||
| ECHA InfoCard | 100.044.767 | ||
| KEGG |
| ||
| UNII | |||
| |||
| |||
| Properties | |||
| C10H14N4O2 | |||
| Molar mass | 222.3 g/mol | ||
| Appearance | White solid | ||
| Melting point | 199 to 201 °C (390 to 394 °F; 472 to 474 K) | ||
| Solubility | Soluble in ethanol, DMSO, and methanol | ||
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |||
IBMX (3-isobutyl-1-methylxanthine), like othermethylxanthine derivatives, is both a:
As aphosphodiesterase inhibitor, IBMX hasIC50 = 2–50μM[6] and does not inhibitPDE8 orPDE9.[7]